FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Settingbenzinga.comFDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options.
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timelinebenzinga.comTrump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patientsbenzinga.comArgenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across multiple studies.
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunityinvestors.comAnalysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.investors.comBiotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approvalbenzinga.comBiohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones.
